Borui Pharmaceuticals: Plans to increase capital by 30 million yuan in its equity affiliate, Laitekang

LightningPacketLoss · 2026-03-11T18:30:31+00:00

Borui Pharmaceutical announced a capital increase of 30 million yuan to its equity affiliate, Laite Kang. After the capital increase, the shareholding will be 16.52%. This related-party transaction does not constitute a major asset restructuring and does not require shareholder approval.

LightningPacketLoss

2026-03-11 18:30:31

Abstract generation in progress

Recently, Borui Pharmaceutical announced that the company plans to invest an additional 30 million yuan in its associate company, Laitakang (Suzhou) Biopharmaceutical Co., Ltd., with a subscribed capital increase of 4.6119 million yuan. The remaining amount will be recorded as capital reserve of the target company. After this capital increase, the company will hold a 16.52181% stake in Laitakang. This transaction constitutes a related-party transaction, and Chairman Yuan Jiandong serves as a member of the decision-making committee of Langyu Yuanfeng Investment. The transaction does not constitute a major asset reorganization and does not require shareholder approval.

(Borui Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.